[Zurück]


Zeitschriftenartikel:

A.A. Soliman, O. Alajrawy, F. Attaby, W. Linert:
"New binary and ternary platinum(II) formamidine complexes: synthesis, characterization, structural studies and in-vitro antitumor activity";
Journal of Molecular Structure, 1115 (2016), S. 17 - 32.



Kurzfassung englisch:
A series of new binary and ternary platinum(II) complexes of the type [Pt(L1-4)Cl2].xH2O and [Pt(L1-4)ox].xH2O where L = formamidine ligands and ox = oxalate, have been synthesized and characterized by elemental analyses, magnetic susceptibility, UV-vis, infrared (IR), mass spectroscopy, thermal analysis and theoretical calculations. The spectroscopic data indicated that the formamidine ligands act as bidentate N2 donors. The complexes (1-8) are diamagnetic and the optimization of their structures indicated that the geometry is distorted square planar with Cl-Pt-Cl, O-Pt-O and N-Pt-N bond angles ranged 81.73°-95.82° which is acceptable for the heteroleptic complexes. The electronic energies (a.u.) of the complexes (−893.53 to −1989.84) indicate that the complexes are more stable than the ligands. The energies of the HOMO (−0.218 to −0.244) and LUMO (−.0111to −0.134) orbitals of the complexes were negative which indicates that the complexes are stable compounds. The dipole moment of the complexes (6.23-19.89 Debye) indicates that the complexes are polarized. The complexes are thermally stable as shown from their relatively higher overall activation energies (889-2066 kJ mol-1). The complexes are proved to have a good cytotoxicity with IC50 (μM) against MCF-7 (0.040-0.117), HCT-116 (0.085-0.119) and HepG-2 (0.058-0.131) cell lines, which open the field for further application as antitumor compounds.

Schlagworte:
Pt(II) complexes; Ternary complexes; Formamidine; Cytotoxicity; DFT calculations


"Offizielle" elektronische Version der Publikation (entsprechend ihrem Digital Object Identifier - DOI)
http://dx.doi.org/10.1016/j.molstruc.2016.02.073


Erstellt aus der Publikationsdatenbank der Technischen Universität Wien.